Teva, Novartis End Patent Spat Over Zometa

Law360, New York (July 16, 2010, 5:56 PM EDT) -- A judge has dismissed a patent infringement suit between Teva Pharmaceuticals Industries Ltd. and Novartis Corp. over a generic version of the Swiss drugmaker's bone treatment Zometa.

Judge Sue L. Robinson of the U.S. District Court for the District of Delaware signed off Friday on the parties' stipulation of dismissal. The stipulation, which Teva and Novartis filed July 9, dismisses without prejudice all claims, counterclaims and defenses in the action.

Both Teva and Novartis will pay their own costs and attorneys' fees, according to the stipulation....
To view the full article, register now.